List of Excipients in Branded Drug KORSUVA

KORSUVA Excipient Strategy, Formulation Patents, Exclusivity and Commercial Opportunities

Last updated: September 1, 2026

KORSUVA (difelikefalin) is a ready-to-use intravenous product for treating moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Its commercial formulation is intentionally simple: a low-dose aqueous solution in a single-dose prefilled syringe. The main excipient opportunity is not reformulating the existing product for routine use. It is extending difelikefalin into easier-to-administer, lower-cost, and non-dialysis delivery formats while preserving chemical stability and predictable exposure.

KORSUVA's core commercial constraints are its dialysis-center administration model, narrow labeled population, renal elimination, and reliance on post-dialysis intravenous dosing. These constraints create opportunities for oral, subcutaneous, depot, and dialysis-integrated products, but each route presents meaningful formulation and regulatory barriers.

What is KORSUVA and which excipients does it contain?

KORSUVA contains difelikefalin acetate, a selective kappa opioid receptor agonist. The U.S. product is an intravenous injection supplied at 50 micrograms/mL in a single-dose prefilled syringe. The FDA-approved indication covers moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The recommended dose is 0.5 micrograms/kg, administered into the venous line of the dialysis circuit after the patient has been disconnected from the dialysis machine or intravenously after hemodialysis [1].

The U.S. label identifies the following inactive ingredients:

Component	Function in the formulation
Acetic acid	pH adjustment
Sodium acetate trihydrate	Buffering capacity
Sodium chloride	Tonicity adjustment
Water for injection	Vehicle

The formulation does not rely on a complex surfactant system, preservative system, lipid carrier, or particulate delivery platform. It is a low-excipient injectable product designed for single use.

What is the KORSUVA formulation profile?

The formulation strategy has four commercial advantages:

1. It minimizes excipient-related tolerability concerns.
2. It avoids antimicrobial preservatives in a single-dose product.
3. It supports prefilled-syringe presentation.
4. It fits existing dialysis workflow without requiring reconstitution.

The same simplicity limits product differentiation. A follow-on product using the same route and excipients would likely compete primarily on price, supply reliability, device convenience, and contracting rather than on a materially differentiated clinical profile.

What excipient strategy supports KORSUVA stability and administration?

The current formulation uses a conventional acetate-buffered saline vehicle. For a peptide-like or small modified peptide active ingredient such as difelikefalin, the key formulation risks are pH-dependent degradation, adsorption to container surfaces, aggregation or particulate formation, and compatibility with the syringe and dialysis-line materials.

pH and buffer selection

The acetate system provides a mildly acidic environment intended to support chemical stability. A follow-on developer would normally screen:

• Acetate buffers across a narrow acidic pH range.
• Citrate and phosphate alternatives.
• Buffer concentration and ionic strength.
• Compatibility with elastomeric syringe components.
• Visible and subvisible particulate formation during storage.

Replacing acetate with phosphate or citrate would not automatically create a commercial advantage. A buffer change would need to improve shelf life, reduce container interaction, enable a higher concentration, or support another route of administration.

Tonicity and injection tolerability

Sodium chloride provides isotonicity adjustment. A reformulation could examine alternative tonicity agents such as dextrose or mannitol, but the benefit would need to be measurable. A different tonicity agent could affect viscosity, osmolality, aggregation behavior, or container compatibility.

For intravenous administration in a dialysis setting, low injection volume and predictable osmolality are more commercially valuable than cosmetic excipient changes.

Preservatives and multidose presentations

A multidose KORSUVA presentation would create operational advantages only if the product could maintain microbiological integrity over repeated withdrawals. That approach would introduce preservative exposure and potentially complicate dialysis-center handling. A multidose product is less attractive than a single-dose cartridge or vial unless it materially reduces waste and acquisition cost.

Container-closure system

The prefilled syringe is part of the formulation strategy. Important development variables include:

• Glass versus polymer syringe barrels.
• Silicone oil levels.
• Needle and stopper materials.
• Extractables and leachables.
• Protein or peptide adsorption.
• Shipping vibration and freeze-thaw performance.
• Compatibility with automated pharmacy or dialysis-center systems.

A container-closure patent may provide more practical protection than a new buffer composition if it improves shelf life, reduces preparation steps, or enables a proprietary delivery device.

What formulation patents could protect KORSUVA follow-on products?

Formulation protection for difelikefalin could cover more than the marketed excipient list. Potential claim categories include:

Patent category	Potential commercial subject matter
Aqueous injectable composition	Difelikefalin concentration, pH, buffer, tonicity and impurity limits
Stability composition	Reduced degradation products during refrigerated or room-temperature storage
Prefilled syringe	Container materials, syringe geometry, stopper composition and dose delivery
Dialysis administration	Administration through the venous line after hemodialysis
Subcutaneous formulation	Higher concentration, viscosity control and injection-volume reduction
Oral formulation	Permeation enhancement, absorption control, enteric protection or solid dispersion
Long-acting delivery	Depot, microparticle, implant or sustained-release matrix
Manufacturing process	Purification, impurity removal, crystallization, concentration and fill-finish controls

The strongest formulation claims would link a defined composition to an unexpected technical result, such as materially improved stability, lower impurity formation, reduced adsorption, or improved bioavailability. A claim that merely recites difelikefalin, water, sodium chloride and a routine buffer would face greater obviousness risk if similar opioid-peptide formulations were known.

What manufacturing barriers affect difelikefalin competition?

The commercial product uses a low dose, which increases the importance of content uniformity, assay accuracy and low-level impurity control. Manufacturing barriers may include:

• Consistent synthesis or peptide production.
• Control of stereochemistry and related impurities.
• Reliable low-concentration dilution.
• Sterile filtration or aseptic processing.
• Low-bind container selection.
• Validated fill volumes for prefilled syringes.
• Stability-indicating analytical methods.
• Supply of specialized syringe components.

These barriers are meaningful but do not appear equivalent to the manufacturing complexity of a monoclonal antibody or cell therapy. A capable generic injectable manufacturer could potentially develop a competing product, subject to regulatory requirements and any enforceable patents or exclusivity.

When does KORSUVA lose regulatory exclusivity?

KORSUVA received FDA approval on August 23, 2021. The approval was supported by the 505(b)(2) pathway, according to the FDA approval announcement and product materials [2]. The product received five years of new chemical entity exclusivity if FDA determined that difelikefalin qualified as an NCE. That period would generally run from the approval date and would prevent submission of an ANDA or 505(b)(2) application relying on the reference product during the exclusivity period, subject to statutory exceptions.

The initial five-year period would therefore expire in August 2026. A 505(b)(2) or ANDA applicant could potentially submit with a Paragraph IV certification beginning in August 2025, one year before the five-year exclusivity expiration, if the statutory requirements are met. Approval would still depend on any listed patents, regulatory exclusivity, and FDA review timing.

Milestone	Date or status
FDA approval of KORSUVA injection	August 23, 2021
Five-year NCE exclusivity, if applicable	Generally through August 2026
Earliest potential Paragraph IV submission window	Generally August 2025
Pediatric exclusivity	No pediatric extension is assumed here
Biosimilar exclusivity	Not applicable; difelikefalin is a small-molecule drug
Patent expiry	Requires current Orange Book patent-by-patent verification

FDA regulatory exclusivity and patent expiry are separate. A drug can remain patent-protected after NCE exclusivity ends, and a patent challenge can occur before patent expiry.

What is the Orange Book status of KORSUVA?

The FDA Orange Book is the controlling source for listed KORSUVA patents, expiration dates and use codes. A commercial assessment should distinguish among:

• Drug substance patents.
• Drug product or formulation patents.
• Method-of-use patents.
• Device or presentation patents that may or may not be Orange Book listable.
• Regulatory exclusivity.
• Patents listed against the reference product rather than against a separate international brand.

KORSUVA's FDA label establishes the reference product, dosage form and indication. It does not by itself establish the complete patent estate. Orange Book records should be reviewed for each listed patent, filing history and patent-use code before making a launch or Paragraph IV decision [1, 3].

Which companies are challenging KORSUVA?

No specific Paragraph IV challenger, ANDA applicant, or final settlement should be treated as established without a current FDA Orange Book and court-docket review. The most likely competitive entrants are injectable generic manufacturers with sterile fill-finish capacity and companies developing alternative difelikefalin routes.

The competitive field can include:

• Generic injectable manufacturers.
• Specialty pharmaceutical companies focused on renal care.
• Drug-delivery companies developing subcutaneous or oral systems.
• Existing dialysis suppliers with access to nephrology purchasing channels.
• Licensees seeking rights outside the United States.

A generic injection would likely be the first direct threat. An oral or subcutaneous product would be a product-extension threat rather than a conventional generic threat.

What generic launch risks exist for KORSUVA?

The launch scenarios are route-dependent.

Scenario 1: Injectable generic after regulatory and patent clearance

This is the most direct threat. The product would replicate the approved route and indication and compete through lower acquisition cost. The principal barriers would be listed patents, ANDA certification strategy, injectable manufacturing validation and dialysis-center contracting.

Scenario 2: Authorized generic

An authorized generic could reduce the price gap and preserve formulary access for the originator's commercial organization. It could also be used to manage the transition after patent expiry.

Scenario 3: 505(b)(2) reformulation

A 505(b)(2) applicant could pursue a different concentration, container, route or dosing method. A differentiated formulation could obtain its own patents and potentially avoid direct substitution rules that apply to an ANDA.

Scenario 4: Non-difelikefalin competitors

Other treatments for chronic kidney disease-associated pruritus, including oral kappa opioid receptor approaches and non-opioid therapies, can compete for the same nephrology budget. These products would not need to overcome KORSUVA's patents but would need to demonstrate acceptable efficacy, safety and dialysis-population utility.

What commercial opportunities exist for KORSUVA excipient and delivery innovation?

The largest opportunities involve changing administration economics rather than optimizing the existing intravenous vehicle.

Subcutaneous KORSUVA

A subcutaneous product could allow administration outside the dialysis chair, reduce venous-line handling, and expand use in dialysis settings with limited nursing capacity. Development challenges include injection volume, local tolerability, concentration, viscosity, syringeability and dose accuracy.

A concentrated formulation using the same active ingredient and a low-volume injection device could support a product with meaningful commercial differentiation.

Oral difelikefalin

An oral product would have the broadest commercial potential because it could address patients outside the hemodialysis population. Oral delivery is technically difficult if the active ingredient has limited permeability, poor stability in the gastrointestinal tract, or substantial first-pass loss.

Excipient strategies could include:

• Permeation enhancers.
• Enteric protection.
• Lipid-based systems.
• Mucoadhesive carriers.
• Solid dispersions.
• Nanoparticle or amorphous systems.
• Enzyme-protection approaches.

The commercial value would be high, but the regulatory pathway could involve new clinical studies and may not support simple reliance on the approved injection.

Long-acting injectable

A depot or sustained-release product could reduce administration frequency and improve adherence. Candidate platforms include biodegradable microspheres, in situ depots and implantable systems. The main risks are dose dumping, local tolerability, manufacturing complexity and difficulty reversing exposure in patients with advanced renal disease.

Dialysis-compatible packaging

A lower-risk opportunity is workflow optimization:

• Ready-to-use cartridges.
• Unit-dose vials with lower residual volume.
• Barcode-enabled syringes.
• Packaging designed for dialysis medication carts.
• Lower-waste presentations.
• Device integration with dialysis-center inventory systems.

These improvements may support contracting advantages even if they do not create broad patent protection.

How does KORSUVA compare with competing renal-pruritus therapies?

Attribute	KORSUVA	Oral or non-opioid competitors
Active ingredient	Difelikefalin	Varies by product
Approved route	Intravenous after hemodialysis	Often oral or topical, depending on product
Core population	Adults on hemodialysis with CKD-associated pruritus	May include broader CKD populations
Administration control	High, because dialysis staff administer the dose	Depends on patient adherence
Formulation complexity	Low for the marketed injection	Ranges from conventional tablets to complex delivery systems
Main commercial strength	Integration with dialysis workflow	Potentially broader use outside dialysis
Main weakness	Dependence on dialysis-center administration	Adherence, systemic exposure or narrower evidence base
Best lifecycle opportunity	Subcutaneous, oral or depot delivery	Improved efficacy, tolerability or convenience

KORSUVA's competitive position is strongest when dialysis-center administration is viewed as a benefit. It is weaker when patients, physicians or payers prioritize home treatment and broad use across chronic kidney disease populations.

What licensing deals and regional opportunities affect KORSUVA?

Vifor Pharma, now part of CSL, commercializes KORSUVA in the United States under the CSL Vifor organization. Cara Therapeutics discovered difelikefalin and has been a central development and commercialization participant. Outside the United States, the product is marketed as Kapruvia in Europe and other jurisdictions through regional commercialization arrangements [2, 4].

Potential licensing opportunities include:

• Regional rights in countries with large dialysis populations.
• Co-development of oral or subcutaneous formulations.
• Device partnerships for prefilled or autoinjector systems.
• Manufacturing licenses for sterile fill-finish.
• Co-promotion with dialysis service providers.
• Formulation licensing for improved stability or room-temperature storage.

Geographic value depends on dialysis prevalence, reimbursement, regulatory recognition of CKD-associated pruritus and local manufacturing requirements. The European and U.S. markets provide the clearest reference points, while emerging dialysis markets may favor lower-cost presentations and local supply.

How strong is the KORSUVA patent estate?

Patent strength depends on claim scope, remaining term, Orange Book listing, prosecution history and the ability to obtain injunctive relief against a follow-on product. The commercial formulation itself is relatively simple, which may limit the defensibility of narrow excipient claims.

The strongest protection would likely come from a coordinated estate covering:

• Difelikefalin composition of matter.
• Approved therapeutic use.
• Formulation and stability.
• Prefilled syringe or device presentation.
• Alternative routes of administration.
• Manufacturing and purification.

Method-of-use patents may remain commercially valuable even after composition patents expire, but their effectiveness depends on labeling, physician prescribing behavior and the ability to establish induced infringement. Formulation patents are more valuable when they cover a required product attribute, such as a stable high-concentration subcutaneous formulation, rather than a readily substituted buffer system.

Key Takeaways

• KORSUVA is a simple acetate-buffered, saline-based intravenous difelikefalin formulation.
• Its largest commercial limitation is post-hemodialysis intravenous administration.
• Excipient optimization alone is unlikely to create major market expansion.
• Subcutaneous, oral and long-acting formulations offer the strongest lifecycle opportunities.
• Single-dose, dialysis-compatible packaging can improve workflow and contracting economics.
• KORSUVA's five-year NCE exclusivity would generally run through August 2026 if the product qualified for NCE treatment.
• A potential Paragraph IV submission window would generally begin one year before the end of five-year NCE exclusivity, subject to statutory requirements.
• Difelikefalin is a small molecule, so biosimilar risk does not apply. Generic and 505(b)(2) risk does.
• Patent value depends on composition-of-matter, method-of-use, formulation, device and manufacturing coverage, not the marketed excipient list alone.
• Current Orange Book records and court dockets control any final assessment of patent expiry, Paragraph IV challenges and settlement status.

FAQs

Can KORSUVA be reformulated as an oral capsule?

Yes, but an oral product would require evidence that difelikefalin can achieve adequate systemic exposure through the gastrointestinal tract. Permeation enhancement, enteric protection and lipid-based delivery are possible strategies, but the product could require a new clinical development program.

Is KORSUVA a biologic eligible for biosimilar competition?

No. Difelikefalin is a chemically defined small-molecule drug. Competitive products would generally use an ANDA or 505(b)(2) pathway rather than the biosimilar pathway.

Which KORSUVA excipient offers the greatest patent opportunity?

The strongest opportunity is unlikely to be a routine buffer substitution. Higher-value claims would connect an excipient system to a measurable result, such as high-concentration stability, subcutaneous tolerability, reduced adsorption or extended shelf life.

Could a generic KORSUVA injection automatically substitute at the pharmacy?

Automatic substitution depends on FDA approval as a therapeutically equivalent product, state substitution law and the dispensing setting. Dialysis-center administration and institutional purchasing may create different substitution and contracting dynamics from retail pharmacy dispensing.

What is the most valuable KORSUVA lifecycle product?

A low-volume subcutaneous product is likely the most practical near- to medium-term extension because it could improve administration convenience without requiring the permeability solutions needed for oral delivery. An oral product has greater market-expansion potential but also greater technical and clinical risk.

References

1. U.S. Food and Drug Administration. (2024). KORSUVA (difelikefalin) injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (2021, August 23). FDA approves first treatment for chronic kidney disease-associated pruritus in adults on hemodialysis. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. European Medicines Agency. (2022). Kapruvia: EPAR product information. EMA.